Varaico: Literature-Extracted Genetic Variants

Gene:CYP2C19
Variant:p.P227P
Back to variants list

CYP2C19

NM_000769.4:p.P227P

Associated Papers

Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: Systematic review and meta-analysis.

Kremers FC et al.

International Journal of Stroke : Official Journal of the International Stroke Society, 2026

Association of CYP2C19 polymorphism with cyclophosphamide-induced toxicity in systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis.

Jha A et al.

Lupus, 2026

Association of CYP2C19 Single Nucleotide Polymorphism With Hemorrhagic Cystitis After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.

Zhang W et al.

Clinical Transplantation, 2026

Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption.

Schulte J et al.

International Journal of Legal Medicine, 2026

Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.

Krebs K et al.

Npj Genomic Medicine, 2026

41549095 (PubMed )
Supplement: 41525_2025_549_MOESM2_ESM.xlsx › Supplementary_Data_6

Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.

Tremmel R et al.

Clinical Pharmacology and Therapeutics, 2026

41074844 (PubMed )
Supplement: CPT-119-241-s005.pdf

Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses.

Jiang Z et al.

Frontiers in Pharmacology, 2026

Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug-drug interaction study in liver transplant recipients.

Li J et al.

Therapeutic Advances in Drug Safety, 2026

Association Between CYP2C9 and CYP2C19 Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy.

Alvarado AT et al.

Pharmaceuticals (basel, Switzerland), 2025

Single-tube Lambda exonuclease-mediated LbuCas13a detect of ssDNA for single-nucleotide polymorphisms genotyping.

Luo S et al.

Biosensors & Bioelectronics, 2025

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.

Shenoy PV et al.

Cancer Metastasis Reviews, 2025

41199076 (PubMed )
Supplement: 10555_2025_10299_MOESM1_ESM.xlsx › Gene_and_SNP_details

CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke.

Chen Y et al.

Stroke, 2025

An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.

Sychev DA et al.

Pharmaceuticals (basel, Switzerland), 2025

The role of genetic polymorphisms on drug response in Alzheimer's disease: a systematic review.

Climacosa FMM et al.

Bmc Medical Genomics, 2025

41068898 (PubMed )
Supplement: 12920_2025_2225_MOESM3_ESM.xlsx › CYP

Custom Gene Panel Analysis Identifies Novel Polymorphisms Associated with Clopidogrel Response in Patients Undergoing Percutaneous Coronary Intervention with Stent.

Antúnez-Rodríguez A et al.

International Journal of Molecular Sciences, 2025

Prevalence of CYP2C19 Poor Metabolisers 
Among South Indian Psychiatric Patients: 
A Pharmacogenetic Perspective Toward 
Precision Psychopharmacology.

Sukumaran B et al.

Annals of Neurosciences, 2025

CYP2D6 and CYP2E1 Gene Polymorphisms and Their Influence on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.

Gudur RA et al.

Asian Pacific Journal of Cancer Prevention : Apjcp, 2025

Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study.

Jeong E et al.

Pharmacotherapy, 2025

Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India.

Bharath G et al.

Scientific Reports, 2025

41028360 (PubMed )
Supplement: 41598_2025_96338_MOESM1_ESM.pdf

ABCB1 polymorphisms are associated with clinical response to nabiximols in patients with multiple sclerosis-related spasticity.

Gemma A et al.

Journal of Cannabis Research, 2025

Constant Temperature Electrochemical Biosensor for SNP Detection in Human Genomic DNA Based on DNA Melting Analysis.

Serapinas S et al.

Acs Sensors, 2025

XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestries.

Siddiqui MK et al.

Communications Medicine, 2025

40993285 (PubMed )
Supplement: 43856_2025_1076_MOESM1_ESM.pdf

CYP2C19 Loss-of-Function Is an Independent Risk Factor of Coronary Artery Disease in Patients With Hypertension.

Wei G et al.

Journal of Clinical Laboratory Analysis, 2025

Influence of pharmacokinetics-related gene polymorphisms on plasma levels of clozapine and its metabolites in Japanese patients with schizophrenia.

Kinoshita S et al.

Pcn Reports : Psychiatry and Clinical Neurosciences, 2025

Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.

Naderi N et al.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025

Genetic and clinical factors associated with the metabolism of valproic acid in post-neurosurgery patients.

Cai X et al.

Progress in Neuro-psychopharmacology & Biological Psychiatry, 2025

Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes-Pharmacogenomic Impact on Inter-Organ Communication.

Figueiral M et al.

Comprehensive Physiology, 2025

CYP2C19-Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients.

Katada Y et al.

Clinical and Translational Science, 2025

Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024.

Fornaguera A et al.

Journal of Clinical Medicine, 2025

Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population.

Hikino K et al.

British Journal of Clinical Pharmacology, 2025

Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.

Díaz-Villamarín X et al.

Journal of Personalized Medicine, 2025

The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.

Haj Saleh N et al.

Bmc Cardiovascular Disorders, 2025

The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.

Akkaif MA et al.

Cardiovascular Drugs and Therapy, 2025

Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.

Park HJ et al.

Archives of Pharmacal Research, 2025

The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.

Wang LY et al.

Innovation (cambridge (mass.)), 2025

39991480 (PubMed )
Supplement: mmc5.xlsx › Sheet1

Cytochrome P450 17 (CYP17), CYP2C19*2, CYP2C19*3 Gene Polymorphisms and Gastrointestinal Cancer Risk in Rural Maharashtra: A Hospital based Case-Control Study.

Datkhile KD et al.

Asian Pacific Journal of Cancer Prevention : Apjcp, 2025

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.

Lebreton L et al.

Clinical Pharmacology and Therapeutics, 2025

The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.

Cacabelos R et al.

Expert Opinion on Drug Metabolism & Toxicology, 2025

Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.

Litonius K et al.

Clinical Pharmacology and Therapeutics, 2025

39365028 (PubMed )
Supplement: CPT-117-278-s001.pdf

Prevalence of CYP2C19 Variants in Patients with Cardiovascular Disease from the Yunnan-Guizhou Plateau in Southwestern China.

Li XP et al.

Pharmacogenomics and Personalized Medicine, 2025

The Frequency of CYP2C19*2 Gene Polymorphisms in Burkina Faso Patients Treated with Clopidogrel.

Kagambèga YD et al.

The Application of Clinical Genetics, 2025

Impact of cyclosporine A-related single nucleotide polymorphisms on post-transplant outcomes in pediatric hematologic malignancy patients undergoing allogeneic hematopoietic stem cell transplantation.

Ji Q et al.

Frontiers in Immunology, 2025

Post-transplant complications revealed by mycophenolate mofetil related transporters and metabolic enzymes gene polymorphisms in pediatric patients with hematological disorders.

Ji Q et al.

Bmc Cancer, 2024

Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.

Roncato R et al.

Jama Network Open, 2024

39641926 (PubMed )
Supplement: jamanetwopen-e2449441-s001.pdf

Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.

Shoji K et al.

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 2024

Association of CYP2C19*2 c.681G>A (rs4244285) Loss-of-function Allele with Cardiovascular Disease Risk in the Kosovo Population.

Elshani N et al.

Balkan Journal of Medical Genetics : Bjmg, 2024

1–50 of 702 papers
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."